Drug Profile
NI 307
Alternative Names: NI-307Latest Information Update: 07 Jun 2021
Price :
$50
*
At a glance
- Originator Neurimmune Therapeutics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Viral protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Progressive multifocal leukoencephalopathy
Most Recent Events
- 07 Jun 2021 NI 307 is still in early research in Progressive multifocal leukoencephalopathy in Switzerland (Parenteral) (Neurimmune pipeline June 2021)
- 28 May 2021 No recent reports of development identified for research development in Progressive multifocal leukoencephalopathy in Switzerland
- 27 Apr 2017 Early research in Progressive multifocal leukoencephalopathy in Switzerland (Parenteral) (Neurimmune pipeline)